MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Analyst Ratings
USA - NASDAQ:MREO - US5894921072 - ADR
1.92 USD
+0.15 (+8.47%)
ChartMill assigns a Buy % Consensus number of 88% to MREO. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.14. This target is 271.88% above the current price.
MREO was analyzed by 15 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about MREO.
In the previous month the buy percentage consensus was at a similar level.
MREO was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-25 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-07-10 | Needham | Maintains | Buy -> Buy |
| 2025-05-13 | Needham | Reiterate | Buy -> Buy |
| 2025-04-09 | Needham | Reiterate | Buy -> Buy |
| 2025-03-27 | JP Morgan | Initiate | Overweight |
| 2025-03-26 | Needham | Reiterate | Buy -> Buy |
| 2025-03-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-01-13 | Needham | Reiterate | Buy -> Buy |
| 2024-12-24 | LifeSci Capital | Initiate | Outperform |
| 2024-12-06 | Jefferies | Initiate | Buy |
| 2024-11-12 | Needham | Reiterate | Buy -> Buy |
| 2024-10-01 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-13 | Needham | Reiterate | Buy -> Buy |
| 2024-07-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-06-20 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-06-13 | Baird | Initiate | Outperform |
| 2024-06-12 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-06-12 | Needham | Maintains | Buy -> Buy |
| 2024-05-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-05-16 | Needham | Reiterate | Buy -> Buy |
| 2024-04-10 | Needham | Reiterate | Buy -> Buy |
| 2024-03-28 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-28 | Needham | Maintains | Buy -> Buy |
| 2024-03-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-09-08 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-09-08 | Needham | Reiterate | Buy -> Buy |
| 2023-08-23 | Needham | Reiterate | Buy -> Buy |
| 2023-06-06 | Needham | Reiterate | Buy -> Buy |
| 2023-05-26 | Needham | Reiterate | Buy -> Buy |
MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ
What is the average price target for MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
15 analysts have analysed MREO and the average price target is 7.14 USD. This implies a price increase of 271.88% is expected in the next year compared to the current price of 1.92.
What is the consensus rating for MREO stock?
The consensus rating for MEREO BIOPHARMA GROUP PL-ADR (MREO) is 88 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for MREO stock?
The number of analysts covering MEREO BIOPHARMA GROUP PL-ADR (MREO) is 15.